ClinicalTrials.gov registry snapshot / 2026-07-24

Peptide trials,
without the maze.

Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.

268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program

Study status is not drug rank.

Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.

Official registry finder

Filter the exact records.

Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.

Reset
14matching registry records
Matching recruiting site observations2
Program and recordStatusPhase and enrollmentLocationsPrimary completionRegistry updateSource
The Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432 / RAMBO / Novo Nordisk A/SRecruitingVerified 2025-07Phase 1144 estimated1 matching recruitingHerlev, 2730, DenmarkMay 3, 2028estimatedJul 25, 2025ClinicalTrials.govOpen NCT07010432
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 3460 estimated0 matching recruitingNo city or postal detail is present for the matching registry rows.Mar 20, 2030estimatedJul 17, 2026ClinicalTrials.govOpen NCT07253285
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195 / RASMUS / Novo Nordisk A/SRecruitingVerified 2026-05Phase 1100 estimated1 matching recruitingAarhus N, 8200, DenmarkApr 28, 2028estimatedMay 7, 2026ClinicalTrials.govOpen NCT07527195
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 / REDEFINE 1 / Novo Nordisk A/SActive, not recruitingVerified 2026-07Phase 33,400 estimated0 matching recruitingNo city or postal detail is present for the matching registry rows.Oct 30, 2024actualJul 17, 2026ClinicalTrials.govOpen NCT05567796
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 / REDEFINE 3 / Novo Nordisk A/SActive, not recruitingVerified 2026-07Phase 37,101 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Sep 1, 2027estimatedJul 17, 2026ClinicalTrials.govOpen NCT05669755
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449 / Novo Nordisk A/SActive, not recruitingVerified 2026-01Phase 3400 estimated0 matching recruitingNo city or postal detail is present for the matching registry rows.Aug 28, 2028estimatedJan 20, 2026ClinicalTrials.govOpen NCT06780449
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 / Novo Nordisk A/SActive, not recruitingVerified 2025-12Phase 2142 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Aug 21, 2026estimatedDec 5, 2025ClinicalTrials.govOpen NCT06797869
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.NCT03856047 / Novo Nordisk A/SCompletedVerified 2024-07Registry results postedPhase 2706 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Mar 2, 2020actualJul 5, 2024ClinicalTrials.govOpen NCT03856047
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or ObesityNCT04940078 / Novo Nordisk A/SCompletedVerified 2025-12Phase 140 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Jan 19, 2022actualDec 12, 2025ClinicalTrials.govOpen NCT04940078
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)NCT05016882 / Novo Nordisk A/SCompletedVerified 2025-11Phase 2698 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Dec 17, 2024actualNov 19, 2025ClinicalTrials.govOpen NCT05016882
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 / REIMAGINE 2 / Novo Nordisk A/SCompletedVerified 2026-07Phase 32,734 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Nov 19, 2025actualJul 8, 2026ClinicalTrials.govOpen NCT06065540
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130 / Novo Nordisk A/SCompletedVerified 2026-03Phase 2270 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Nov 21, 2025actualMar 12, 2026ClinicalTrials.govOpen NCT06409130
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740 / Novo Nordisk A/SWithdrawnVerified 2026-07Phase 20 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Aug 25, 2027estimatedJul 9, 2026ClinicalTrials.govOpen NCT07357740
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766 / Novo Nordisk A/SWithdrawnVerified 2026-07Phase 30 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Nov 29, 2027estimatedJul 9, 2026ClinicalTrials.govOpen NCT07357766
Clinical trial finder FAQ

Status, location, and enrollment are different fields.

These answers prevent the most common registry-search errors before a reader follows an official source.

01

Are any Retatrutide clinical trials recruiting?

Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.

02

How do I find a peptide clinical trial near me?

Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.

03

Does Recruiting mean I can join the trial?

No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.

04

Are the drugs in this clinical trial finder FDA approved?

A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.

05

Why do only some registry records show posted results?

11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.

06

How current is the peptide clinical trial data?

The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.

Evidence boundary

A registry finder, not an enrollment service.

A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.

Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.

Read the official API documentation ↗Understand evidence categories →